Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa

Real-World Evaluation of Secukinumab in Moderate-to-Severe Hidradenitis Suppurativa

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07109765

Enrollment

Registered

2025-08-07

Start date

2025-06-01

Completion date

2026-06-01

Last updated

2025-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hidradenitis Suppurativa (HS)

Keywords

Hidradenitis Suppurativa, Secukinumab, ultrasound

Brief summary

This single-center, prospective, observational study aimed to evaluate the efficacy and safety of Secukinumab in treating moderate-to-severe hidradenitis suppurativa (HS). The study was conducted from June 1, 2025, to June 1, 2026, and all participants were treated at the Department of Dermatology, Peking Union Medical College Hospital. The study was approved by the Clinical and Research Ethics Committee of the Chinese Academy of Medical Sciences, Peking Union Medical College Hospital (Ethics Approval No. I-24PJ1844). All procedures involving human participants adhered to the Declaration of Helsinki. Written informed consent form was signed and obtained from the participant.

Interventions

DRUGSecukinumab

secukinumab 300 mg weekly for five weeks, followed by 300 mg monthly subcutaneous injection

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* age ≥18 years * diagnosis of moderate-to-severe HS with Hurley stage II or III * Disease duration of ≥6 months, presence of at least one draining tunnel or two inflammatory nodules * inadequate response to prior treatments, such as antibiotics, isotretinoin, or TNF inhibitors

Exclusion criteria

* active infections (e.g., viral hepatitis, active tuberculosis) * use of other biologics or systemic immunosuppressants within the past three months * severe organ dysfunction (e.g., hepatic or renal failure) * any other conditions that might affect study results

Design outcomes

Primary

Measure	Time frame	Description
Hidradenitis Suppurativa Clinical Response 50 (HiSCR50)	From enrollment to the end of treatment at Week 12	a ≥50% reduction in the combined count of inflammatory nodules and abscesses from baseline, without an increase in the number of abscesses or draining tunnels

Secondary

Measure	Time frame
Dermatology Life Quality Index	From enrollment to the end of treatment at week 12

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026